FDA publishes new Financial Disclosure Guidelines

New Financial Disclosure Guidelines from FDA (Orthopedics This Week) If you own shares in a mutual fund that includes a company for whom you are a clinical investigator for an FDA-sponsored investigation, do you have to disclose that? Can a literature report be considered a covered clinical study? The FDA’s got the answers for you in a new guidance. The “Guidance for Clinical Investigators, Industry, and FDA Staff – Financial Disclosure by Clinical Investigators,” was issued in February and is a revision of 2001 guidance. Applicants who submit a marketing application for a drug, biological product or device are required to submit certain information concerning the compensation to, and financial interests and arrangements of, any clinical investigator conducting clinical studies. This guidance is intended to assist clinical investigators, industry, and FDA staff in interpreting and complying with the regulations governing financial disclosure by clinical investigators. They must certify the absence of certain financial interests and arrangements of clinical investigators that could affect the reliability of data submitted to FDA, or to disclose those financial interests and arrangem...


Unlock the full article and exclusive OrthoStreams insights: in-depth analyses, hot startups, trends, market intel, and Daily Newsletter—for just $1/day.
Subscribe Now—Up your Game !
 

Scroll to Top